Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content


Hot Topics of the Day|PHGKB
Search PHGKB:

Archive

Hot Topics of the Day are picked by experts to capture the latest information and publications on public health genomics and precision health for various diseases and health topics. Sources include published scientific literature, reviews, blogs and popular press articles.

Sign up MyPHGKB to receive the daily hot topic email alert.

Search Archive:
Archived Hot Topics of the Day By Date
50 hot topic(s) found with the query "Hepatitis"

Mystery hepatitis cases in kids linked to unexpected viral suspect
J Kaiser, Science, May 25, 2022 (Posted: Jul 29, 2022 10AM)

Two preliminary studies finding adeno-associated viruses in pediatric hepatitis cases suggest a child’s genetic background and other viruses all act in concert. They used DNA and RNA sequencing of tissue samples from U.K. cases to look for about 200 different virus families. AAV2 jumped out. It was in liver or blood samples in all nine Scottish cases examined and 15 of 16 separate cases from all over the United Kingdom, according to the studies. In contrast, almost none of 158 controls, which included healthy children and children with hepatitis for known reasons, had AAV2. Both studies also found that all but two of 14 sick children tested carried a specific version of a type of gene called HLA that helps shape the body’s response to pathogens. The variant is particularly common in northern Europeans—16% of Scottish people carry it, and it is known to be linked to some autoimmune disorders.

COVID-19 vaccines for children
JS Gerber et al, Science, November 19, 2021 (Posted: Nov 19, 2021 6AM)

Although it is true that most children experience asymptomatic or mild disease, some will get quite sick, and a small number will die. It’s why children are vaccinated against influenza, meningitis, chickenpox, and hepatitis—none of which, even before vaccines were available, killed as many as SARS-CoV-2 per year. Some parents are understandably hesitant to vaccinate their young children. However, a choice not to get a vaccine is not a risk-free choice; rather, it’s a choice to take a different and more serious risk. The biomedical community must strive to make this clear to the public. It could be one of the most important health decisions a parent will make.

Evidence Used to Update the List of Underlying Medical Conditions Associated with Higher Risk for Severe COVID-19
CDC Science Brief, October 14, 2021 Brand (Posted: Oct 16, 2021 8AM)

Chronic lung disease (including bronchiectasis, bronchopulmonary dysplasia, interstitial lung disease, pulmonary hypertension, pulmonary embolism, tuberculosis) and chronic liver disease (including cirrhosis, non-alcoholic fatty liver disease, alcoholic liver disease, and autoimmune hepatitis) were added September 2021 based on evidence published between December 1, 2019 and August 31, 2021 using the updated review methods outlined below. Mental health disorders (such as mood disorders including depression, and schizophrenia spectrum disorders) were added September 2021 based on evidence published between December 1, 2019 and August 31, 2021. No conditions were removed from the previous underlying medical conditions list.

Hepatitis B: a new weapon against an old enemy
TJ Liang, Nature Medicine, October 12, 2021 (Posted: Oct 13, 2021 7AM)

Chronic infection with hepatitis B virus (HBV) afflicts more than 250 million people worldwide. Effective vaccines and treatments that potently suppress viral levels and reduce liver inflammation have been available for over 20 years, but infection with HBV continues to exact a heavy public-health toll. New strategies based on nucleic acid technologies are being exploited to treat chronic hepatitis B—a pilot clinical study of antisense oligonucleotide treatment shows the potential promise of this approach.

Sofosbuvir plus ribavirin and sofosbuvir plus ledipasvir in patients with genotype 1 or 3 hepatitis C virus and severe renal impairment: a multicentre, phase 2b, non-randomised, open-label study
E Lawitz et al, ancet Gastro Hepato, June 9, 2020 (Posted: Jun 11, 2020 8AM)

In this phase 2b study, ledipasvir combined with sofosbuvir for 12 weeks was safe and effective in patients with genotype 1 HCV infection and stage 4–5 chronic kidney disease who were not on dialysis.

CDC Recommendations for Hepatitis C Screening Among Adults in the United States
CDC, April 2020 (Posted: May 02, 2020 11AM)

Predicting Hepatitis B Virus Infection Based on Health Examination Data of Community Population.
Wang Ying et al. International journal of environmental research and public health 2019 Dec 16(23) (Posted: Dec 11, 2019 9AM)

Management of Hepatitis C in 2019.
Marks Kristen et al. JAMA 2019 May (Posted: May 20, 2019 8AM)

Hepatitis C Virus Genetic Variability, Human Immune Response, and Genome Polymorphisms: Which Is the Interplay?
Lapa Daniele et al. Cells 2019 Apr (4) (Posted: Apr 26, 2019 11AM)

World Hepatitis Day
Brand (Posted: Jul 26, 2018 11AM)

Significant SNPs Related to Telomere Length and Hepatocellular Carcinoma Risk in Chronic Hepatitis B Carriers
Mohamadkhani Ashraf et al. Asian Pacific journal of cancer prevention : APJCP 2018 Mar (3) 585-590 (Posted: May 01, 2018 11AM)

Gene Therapy for Chronic HBV-Can We Eliminate cccDNA?
Bloom Kristie et al. Genes 2018 Apr (4) (Posted: May 01, 2018 11AM)

Immunogenetic studies of the hepatitis C virus infection in an era of pan-genotype antiviral therapies - Effective treatment is coming.
Ellwanger Joel Henrique et al. Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases 2017 Aug (Posted: Oct 30, 2017 8AM)

Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy.
Kang Y et al. The Journal of hospital infection 2017 Aug (4) 342-348 (Posted: Jul 27, 2017 7PM)

Viral and host factors associated with outcomes of hepatitis C virus infection (Review).
Yan Zehui et al. Molecular medicine reports 2017 May (5) 2909-2924 (Posted: May 12, 2017 3PM)

New Hepatitis C Infections Nearly Tripled Over Five Years
Brand (Posted: May 12, 2017 3PM)

Viral Hepatitis and Liver Cancer
Brand (Posted: May 11, 2017 0PM)

Study: Genetic markers may predict which HCV, cirrhosis patients improve with treatment
Science Magazine, May 6, 2017 (Posted: May 06, 2017 7PM)

Genetic study reveals how hepatitis C interacts with humans
Oxford University, April 10, 2017 (Posted: Apr 12, 2017 10AM)

Clinical importance of pharmacogenetics in the treatment of hepatitis C virus infection.
Kamal Adina Maria et al. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie 2016 57(2 Suppl) 675-680 (Posted: Apr 05, 2017 11AM)

GHOST Makes Connections in Hepatitis C Virus Transmission
Brand (Posted: Apr 03, 2017 2PM)

Learn the ABCs of Hepatitis
Brand (Posted: May 23, 2016 3PM)

Hepatitis C Kills More Americans than Any Other Infectious Disease
CDC Blog Post, May 6, 2016 Brand (Posted: May 07, 2016 9AM)

Know Hepatitis B Campaign
Learn about Hepatitis B and efforts to promote testing among Asian Americans Brand (Posted: Mar 15, 2016 11AM)

Fine mapping the MHC region identified four independent variants modifying susceptibility to chronic hepatitis B in Han Chinese.
Zhu Meng et al. Human molecular genetics 2016 Mar (6) 1225-32 (Posted: Mar 14, 2016 1PM)

Analysis of hepatitis B virus genotype changes in patients with chronic hepatitis B infection on tenofovir therapy.
Chauhan Ranjit et al. Journal of medical virology 2016 Feb (Posted: Mar 14, 2016 1PM)

Role of genetic polymorphisms in hepatitis C virus chronic infection.
Coppola Nicola et al. World journal of clinical cases 2015 Sep (9) 807-22 (Posted: Oct 21, 2015 9PM)

Genetic susceptibility to hepatitis E viral infection: An enigmatic virus gives up a secret
I Ditah, Hepatology, November 2015 (Posted: Oct 21, 2015 9PM)

Apolipoprotein E and protection against hepatitis E viral infection in American non-Hispanic blacks
L Zhang et al. Hepatology, November 2015 (Posted: Oct 21, 2015 9PM)

Clinical relevance of hepatitis B virus variants.
Gao Shan et al. World J Hepatol 2015 May 18. (8) 1086-96 (Posted: Jul 27, 2015 9AM)

Predictive factors associated with hepatitis C antiviral therapy response.
Cavalcante Lourianne Nascimento et al. World J Hepatol 2015 Jun 28. (12) 1617-31 (Posted: Jul 27, 2015 9AM)

Apolipoprotein E and protection against hepatitis E virus infection in American, non-Hispanic blacks.
Zhang Lyna et al. Hepatology 2015 Jun 11. (Posted: Jul 14, 2015 2PM)

The role of pharmacogenetics in the treatment of chronic hepatitis C infection.
Kawaguchi-Suzuki Marina et al. Pharmacotherapy 2014 Feb (2) 185-201 (Posted: Jul 14, 2015 2PM)

PEG-Interferon-a ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study.
Milara Javier et al. Farm Hosp 2015 Jan-Feb (1) 29-43 (Posted: Jul 14, 2015 2PM)

Serum Interferon-Related MicroRNAs as Biomarkers to Predict the Response to Interferon Therapy in Chronic Hepatitis C Genotype 4.
Motawi Tarek Kamal et al. PLoS ONE 2015 (3) e0120794 (Posted: Jul 14, 2015 2PM)

Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics.
Cusato Jessica et al. Int. J. Antimicrob. Agents 2015 Mar 14. (Posted: Jul 14, 2015 2PM)

Interleukin 28B polymorphisms as predictors of sustained virological response in chronic hepatitis C: systematic review and meta-analysis.
Cariani E et al. Pharmacogenomics J. 2015 Apr 28. (Posted: Jul 14, 2015 2PM)

Comparative Clinical Effectiveness and Value of Novel Interferon-Free Combination Therapy for Hepatitis C Genotype 1: Summary of California Technology Assessment Forum Report
JA Tice et al. JAMA Internal Medicine, July 13, 2015 (Posted: Jul 14, 2015 2PM)

CDC Information- World Hepatitis Day — July 28, 2015
MMWR, July 24, 2015 Brand (Posted: Feb 25, 2015 0PM)

CDC lists pharmacogenomic testing in treatment of hepatitis as tier 2
Brand (Posted: Feb 25, 2015 0PM)

CDC Information: Hepatitis Awareness Month
Brand (Posted: Feb 25, 2015 0PM)

Using advanced molecular techniques for rapid identification of hepatitis C outbreaks
Brand (Posted: Feb 25, 2015 0PM)

CDC information on viral hepatitis
Brand (Posted: Feb 25, 2015 0PM)

Take this 5 minute hepatitis risk assessment
Brand (Posted: Feb 25, 2015 0PM)

Hepatitis
Brand (Posted: Jan 11, 2014 11AM)

Hepatitis is an inflammation of the liver. Viruses are the most common cause of hepatitis, but the condition can also be caused by other infections, heavy alcohol use, toxins, certain medications, and autoimmune disease. There are five main virus types that cause hepatitis---type A, B, C, D and E. Hepatitis A and E are typically caused by ingesting contaminated food or water. Type B commonly occurs through contact with infected blood, semen or other bodily fluid through sex, sharing needles or other drug-injection equipment or from mother to baby at birth.

Hemochromatosis
From NHLBI health topic site Brand (Posted: Jan 11, 2014 11AM)

What Is Hemochromatosis (HE-mo-kro-ma-TO-sis) is a disease in which too much iron builds up in your body (iron overload). Iron is a mineral found in many foods. Too much iron is toxic to your body. It can poison your organs and cause organ failure. In hemochromatosis, iron can build up in most of your body's organs, but especially in the liver, heart, and pancreas. Too much iron in the liver can cause an enlarged liver, liver failure, liver cancer, or cirrhosis (sir-RO-sis). Cirrhosis is scarring of the liver, which causes the organ to not work well. Too much iron in the heart can cause irregular heartbeats called arrhythmias (ah-RITH-me-ahs) and heart failure. Too much iron in the pancreas can lead to diabetes. If hemochromatosis isn't treated, it may even cause death. Overview The two types of hemochromatosis are primary and secondary. Primary hemochromatosis is caused by a defect in the genes that control how much iron you absorb from food. Secondary hemochromatosis usually is the result of another disease or condition that causes iron overload. Most people who have primary hemochromatosis inherit it from their parents. If you inherit two hemochromatosis genes?one from each parent?you're at risk for iron overload and signs and symptoms of the disease. The two faulty genes cause your body to absorb more iron than usual from the foods you eat. Hemochromatosis is one of the most common genetic disorders in the United States. However, not everyone who has hemochromatosis has signs or symptoms of the disease. Estimates of how many people develop signs and symptoms vary greatly. Some estimates suggest that as many as half of all people who have the disease don't have signs or symptoms. The severity of hemochromatosis also varies. Some people don't have complications, even with high levels of iron in their bodies. Others have severe complications or die from the disease. Certain factors can affect the severity of the disease. For example, a high intake of vitamin C can make hemochromatosis worse. This is because vitamin C helps your body absorb iron from food. Alcohol use can worsen liver damage and cirrhosis caused by hemochromatosis. Conditions such as hepatitis also can further damage or weaken the liver. Outlook The outlook for people who have hemochromatosis largely depends on how much organ damage they have at the time of diagnosis. Early diagnosis and treatment of the disease are important. Treatment may help prevent, delay, or sometimes reverse complications of the disease. Treatment also may lead to better quality of life. For people who are diagnosed and treated early, a normal lifespan is possible. If left untreated, hemochromatosis can lead to severe organ damage and even death. ?Acquired hemochromatosis ?Classical hemochromatosis ?Genetic hemochromatosis ?Genetic iron poisoning ?Hereditary hemochromatosis ?Iron overload disease ?Primary hemochromatosis ?Secondary hemochromatosis

Rare disease gene has a key role in chronic hepatitis C infection
Science Magazine, April 30, 2016 (Posted: Jan 01, 2014 0AM)

Autoimmune hepatitis
From NCATS Genetic and Rare Diseases Information Center Brand (Posted: Jan 01, 2011 0AM)

Non-A-E hepatitis
From NCATS Genetic and Rare Diseases Information Center Brand (Posted: Jan 01, 2011 0AM)

Hepatitis E
From NCATS Genetic and Rare Diseases Information Center Brand (Posted: Jan 01, 2011 0AM)


Disclaimer: Articles listed in Hot Topics of the Day are selected by Public Health Genomics Branch to provide current awareness of the scientific literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the Clips, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.
TOP